AlltRNA’s Engineered tRNA Technology Could Offer Hope for Nonsense Mutations
Regardless of the impacted protein, Alltrna is creating designed tRNA medications that can read through premature termination codons and resume production of the impacted...
Nanoparticles Used as Vehicle to Deliver MicroRNAs to Cells and Treat Duchenne Muscular Dystrophy
In a collaboration between the IMDEA Nanociencia Institute (Madrid), Università Cattolica del Sacro Cuore (Rome), and the University of Bordeaux, researchers have made an...
ENCell Confirms Safety of DMD Stem Cell Therapy EN001 in Phase 1 Clinical Trial in Korea
The bio corporation ENCell reported on February 13 that it confirmed the safety and tolerability of its developing next-generation mesenchymal stem cell therapy EN001...
Satellos Announces Completed Enrollment of Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
Satellos Bioscience, a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced it...
Sarcomatrix to Present its Latest Advancements in the Development of its Lead Drug Candidate, S-969
Sarcomatrix Therapeutics, a clinical-stage biotechnology company focused on revolutionizing treatments for muscle-related diseases, today announced its participation at the 2025 BIO CEO & Investor...